论文部分内容阅读
目的:研究分析氨溴索联合布地耐德雾化吸入对新生儿感染性肺炎患者临床疗效与安全性。方法:在2013年2月~2015年2月来我院治疗新生儿感染性肺炎的患者中抽取78例,将其分为对照组和观察组各39例,两组患儿均进行基础治疗。在此基础上给予观察组患儿氨溴索联合布地耐德雾化吸入进行治疗,并观察比较两组有效率、住院时间、不良反应和体征的消失时间。结果:观察组患儿的总有效率显著高于对照组;观察组的住院时间与临床体征的缓解时间均短于对照组,其差异在统计学上有意义(P<0.05)。结论:在基础治疗的基础上,对患有感染性肺炎的新生儿加用氨溴索联合布地奈德雾化吸入能够提高患儿的临床疗效。
Objective: To study the clinical efficacy and safety of ambroxol combined with Budesonide inhalation on neonatal pneumonia. Methods: From February 2013 to February 2015, 78 cases of neonatal pneumonia were treated in our hospital. They were divided into control group and observation group of 39 cases. Both groups were given basic treatment. On the basis of this, the patients in the observation group were given ambroxol combined with budesonide inhalation for treatment, and the effective rate, hospitalization time, adverse reactions and disappearance of signs of the two groups were observed and compared. Results: The total effective rate in observation group was significantly higher than that in control group. The hospitalization time and clinical symptom relief time in observation group were shorter than that in control group, and the difference was statistically significant (P <0.05). Conclusion: On the basis of basic treatment, inhalation of ambroxol combined with budesonide for neonates with infectious pneumonia can improve the clinical efficacy of children.